Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by mollevi
Last modified by celine.gongora
Group name EquipeCG
Item Type Journal Article
Title Ductal adenocarcinoma of the prostate: Clinical and biological profiles
Creator Vinceneux et al.
Author Armelle Vinceneux
Author Franck Bruyère
Author Olivier Haillot
Author Thomas Charles
Author Alexandre de la Taille
Author Laurent Salomon
Author Yves Allory
Author Idir Ouzaid
Author Laurence Choudat
Author Morgan Rouprêt
Author Eva Comperat
Author Jean-Baptiste Beauval
Author Patrick Vourc'h
Author Gaëlle Fromont
Abstract BACKGROUND: Ductal adenocarcinoma (DAC) is a rare and aggressive subtype of prostate cancer (PCa). In the present study, we analyzed the clinical and biological characteristics of DAC, in comparison with high grade conventional acinar PCa. METHODS: Samples and data were retrospectively collected from seven institutions and centrally reviewed. Immunohistochemistry was performed on tissue microarrays to assess the expression of candidate proteins, based on the molecular classification of PCa, including ERG, PTEN, and SPINK1. SPOP mutations were investigated from tumor DNA by Sanger sequencing. Relationships with outcome were analyzed using log-rank analysis and multivariable Cox regression. RESULTS: Among 56 reviewed prostatectomy specimens, 45 cases of DAC were finally confirmed. The pathological stage was pT3 in more than 66% of cases. ERG was expressed in 42% of DAC, SPINK1 in 9% (all ERG-negative), and two cases (ERG-negative) harbored a SPOP mutation. Compared to high grade conventional PCa matched for the pathological stage, cell proliferation was higher (P?=?0.04) in DAC, and complete PTEN loss more frequent (P?=?0.023). In multivariate analysis, SPINK1 overexpression (P?=?0.017) and loss of PSA immunostaining (P?=?0.02) were significantly associated with biochemical recurrence. CONCLUSION: these results suggest that, despite biological differences that highlighted DAC aggressiveness, the molecular classification recently proposed in conventional PCa could also be applied in DAC.
Publication The Prostate
Volume 77
Issue 12
Pages 1242-1250
Date Sep 2017
Journal Abbr Prostate
Language eng
DOI 10.1002/pros.23383
ISSN 1097-0045
Short Title Ductal adenocarcinoma of the prostate
Library Catalog PubMed
Extra PMID: 28699202
Tags AFU, Aged, Biomarkers, Tumor, Carcinoma, Ductal, ductal adenocarcinoma, Humans, immunochemistry, Male, Middle Aged, Neoplasm Staging, original, Prostatic Neoplasms, Retrospective Studies, speckle-type POZ protein
Date Added 2018/09/14 - 16:38:17
Date Modified 2019/10/24 - 17:53:38


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés